# Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

> **NCT05798156** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 125 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Rituximab
- **DRUG:** Obinutuzumab
- **DRUG:** Polatuzumab vedotin

## Key facts

- **NCT ID:** NCT05798156
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-20
- **Primary completion:** 2025-04-12
- **Final completion:** 2028-02-28
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05798156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05798156, "Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05798156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*